Advocacy groups filed a lawsuit on behalf of 3 Medicaid recipients challenging Arkansas' Medicaid work requirements; CVS Health announced that its pharmacy benefit manager will target expensive drugs to be excluded from formularies if they are not cost effective; Senate leaders have received a letter from 120 consumer and patient associations on the impact Supreme Court nominee Brett Kavanaugh could have on health policy.
The Trump administration is facing another lawsuit over its decision to allow states to impose work requirements in Medicaid. Similar to an earlier lawsuit over Kentucky’s work requirements, advocacy groups filed a lawsuit on behalf of 3 Medicaid recipients in Arkansas, reported Reuters. The lawsuit claims the administration does not have the capability to approve work requirements under the federal Medicaid law. In June, a federal judge blocked Kentucky’s work requirements.
In a recent white paper, CVS Health announced that its pharmacy benefit manager will target expensive drugs to be excluded from formularies if they are not cost effective. According to The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, CVS Caremark will rely on data from the Institute for Clinical and Economic Review to determine cost effectiveness. CVS has already implemented efforts to curb costs, and the white paper identifies 3 additional strategies it will begin to employ.
Senate leaders have received a letter from 120 consumer and patient associations on the impact Supreme Court nominee Brett Kavanaugh could have on health policy. InsideHealth Policy reported that the Supreme Court might be hearing cases on the constitutionality of the Affordable Care Act, access to women’s healthcare services, state accountability for violating Medicaid requirements, and attempts to roll back Medicaid coverage. Kavanaugh could be a deciding vote on all of these health issues.
Allergies and Asthma Prevalence Rise With Climate Change Extremes and Pollutants
June 30th 2025Increasing environmental events driven by climate change and human activity exacerbate allergy and asthma conditions, further compounded by exposure to persistent pollutants like per-and polyfluoroalkyl substances and microplastics.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL
June 30th 2025Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Read More